MediPharm Phase II Cannabinoid Signal in Dementia Agitation: Proof-of-Concept Without Proof of Viability

MediPharm Labs Achieves Strong Q2 Financials and Positive Phase II LiBBY Trial Results

MediPharm Labs reported strong financial results for Q2 2026, achieving $0.9 million in Adjusted EBITDA, its best quarterly performance since 2019, and returning to positive net income compared to a $3.8 million loss in Q2 2025. Net revenue increased 11% sequentially to $10.0 million, while operating expenses decreased 44% year-over-year. Concurrently, the company announced positive Phase II LiBBY trial results, demonstrating a statistically significant improvement in agitation symptoms in patients with advanced dementia using its proprietary cannabinoid formulation.

• MediPharm Labs delivered its strongest quarterly Adjusted EBITDA since 2019, reaching $0.9 million in Q2 2026. The company also achieved positive net income, a significant improvement from a $3.8 million net loss in Q2 2025, reflecting successful profitability improvement initiatives and a 44% reduction in operating expenses year-over-year.
• The Phase II LiBBY trial met its primary endpoint, showing a statistically significant improvement in agitation symptoms compared to placebo in patients with advanced dementia. This was measured by the Cohen-Mansfield Agitation Inventory at week 2, with sustained improvement over the 12-week treatment period, highlighting the therapeutic potential of MediPharm's proprietary cannabinoid formulation.
• International Medical revenue grew 26% sequentially to $5.8 million, driven by strong performance in Germany, where revenue increased 45% sequentially and 33% year-over-year. Despite a 29% reduction in Veterans Affairs Canada reimbursement rates, the company mitigated the impact through efficiencies and saw Canadian Adult Use and Wellness revenue increase 34% sequentially to $1.5 million.

Positive LiBBY Phase II Results for Advanced Dementia Agitation

The CATIE-AD study evaluated atypical antipsychotics — risperidone, olanzapine, and quetiapine — for the management of behavioral symptoms in community-dwelling patients with Alzheimer's disease. Despite their widespread clinical use, the net risk-benefit profile of these agents was found to be no greater than that achieved with placebo, with notably high placebo response rates observed across the trial. From a safety standpoint, treatment-emergent sedation was a consistent finding across all three agents and was identified as a meaningful mediator of mortality risk in patients with dementia. Of particular concern, sedation compounded pre-existing cognitive impairment and elevated the risk of serious complications, including aspiration pneumonia.

A separate 8-week, rater-blinded, randomized study compared flexibly-dosed quetiapine (50–400 mg/day) versus risperidone (0.5–2 mg/day) in 72 outpatients aged 55–85 years presenting with behavioral and psychological symptoms of dementia (BPSD). Both agents demonstrated meaningful within-group reductions in Neuropsychiatric Inventory (NPI) scores from baseline to Week 8, with clinical improvement observed in 67.6% of quetiapine-treated patients and 71.0% of those receiving risperidone. No between-group differences in efficacy or safety — including extrapyramidal symptoms — were detected. Notably, neither agent produced measurable cognitive deterioration on MMSE or Age-adjusted Concentration Test (AKT) scores. Serious adverse events were reported in four patients (quetiapine, n=3; risperidone, n=1), none of which were considered treatment-related, and no cerebrovascular adverse events or deaths occurred.

The STOP-DEM trial took a different approach, examining continuation versus discontinuation of cholinesterase inhibitors (with or without memantine) in 302 community-dwelling patients with severe dementia, defined by an MMSE score of 10 or less, who had been on treatment for a minimum of three months. Conducted as a randomized, pragmatic, open-label trial with blinded evaluators over a 12-month follow-up period, the study's primary endpoint was a composite of entry into institutional care and functional decline — defined as loss of 2 of 4 basic or 6 of 11 instrumental activities per the Bristol Activities of Daily Living Scale. Secondary outcomes encompassed changes in cognitive state, quality of life, and caregiver burden, providing a comprehensive assessment of the real-world implications of continuing or withdrawing established pharmacotherapy in this vulnerable population.

Unpacking the LiBBY Phase II Trial Design

The trials investigating therapeutic interventions in advanced dementia span a range of designs, from randomized controlled studies to open-label extensions and cross-sectional observational analyses. Collectively, these studies employ validated, dementia-specific outcome measures calibrated to detect meaningful change in severely impaired populations.

• Rivastigmine Patch (ACTION Extension): A 24-week open-label extension of the double-blind ACTION study enrolled patients with severe Alzheimer's disease (n=396), with one cohort continuing the 13.3 mg/24 h patch (n=197) and a second uptitrated from 4.6 mg/24 h to 13.3 mg/24 h (n=199). Primary endpoints encompassed safety and tolerability (adverse events, serious adverse events, discontinuations due to adverse events), alongside efficacy assessed via the ADCS-ADL-SIV, the Severe Impairment Battery (SIB), and the ADCS-Clinical Global Impression of Change (ADCS-CGIC).

• Memantine + Donepezil Combination (RCT): A prospective, randomized, placebo-controlled trial enrolled 404 patients with moderate-to-severe Alzheimer's disease (MMSE 5–14) on stable donepezil therapy, randomized to memantine 10 mg b.i.d. (n=203) or placebo (n=201). The primary endpoint was the 19-item ADCS-ADL Inventory (ADCS-ADL₁₉), supplemented by subscale analyses evaluating higher-level functions and connectedness/autonomy derived from factor analysis.

• Quality of Life — Cross-sectional Study (Japan): Conducted in 105 patients with severe dementia (predominantly female; mean age 87.3 ± 6.3 years), this study utilized a multi-instrument assessment battery including the QUALID-J, Cognitive Test for Severe Dementia, NPI-NH, PSMS, PAINAD, and SCUEQS to characterize quality-of-life determinants in this population.

• Quality of Life — Nursing Home Cross-sectional Study: Enrolling 661 persons with dementia residing in nursing homes, this study assessed quality of life using the QUALID scale alongside the CDR, PSMS, and NPI-Q, providing a broader institutional perspective on functional and behavioral correlates of well-being in advanced disease.

Addressing Unmet Needs in Advanced Dementia Agitation

Advanced dementia remains an area of substantial unmet clinical need, with recent literature highlighting gaps across care settings, patient subgroups, and support structures. Research over the past three years has increasingly focused on identifying vulnerable populations and systemic deficiencies that limit the quality and equity of care delivery.

• Adults with Down Syndrome: This population carries a ~90% lifetime risk for Alzheimer's disease and represents a critical underserved group. Behavioral and Psychological Symptoms of Dementia (BPSD) emerge during the prodromal stage — driven by elevated amyloid-beta and neurofibrillary tau — yet clinicians frequently fail to differentiate these from symptoms attributable to stressful life events or co-occurring medical conditions. Caregiver resources for BPSD management and self-care strategies remain insufficient.

• Nursing Home Residents with Advanced Dementia and Frailty: This population demonstrates a longer median survival (16.5 months, 95% CI: 13.5–19.5) compared to those with incurable cancer (8.1 months) or end-stage organ failure (7.7 months), yet receives substantially fewer in-person clinical reviews (2.4 vs. 4.5 for cancer patients), indicating a structural gap in palliative care resourcing and service planning for this extended trajectory.

• Home-Based Care Recipients: Among individuals receiving home-based palliative care, 14.4% experienced non-concordance between their preferred and actual final place of care — driven by factors including higher caregiver burden, psychosocial challenges, infection proximate to death, and better-than-expected prognosis — underscoring the need for more responsive, preference-aligned care planning.

• Palliative Care Access and Referral Standardization: Evidence on the effectiveness of palliative care interventions in advanced dementia remains limited, and criteria for specialist referral lack consensus uptake. International experts have aligned on 15 major and 42 minor referral criteria spanning dementia type, symptom distress, psychosocial and decision-making factors, comorbidities, and hospital utilization patterns — but implementation in practice remains inconsistent.

• Caregiver Burden and Decision-Making Support: Palliative care interventions have demonstrated efficacy in reducing decision-making conflict among caregivers, but effects on caregiver satisfaction and psychological distress require further investigation. Caregivers involved in hand-feeding — particularly in regions with limited support infrastructure — represent a notably high-burden subgroup with inadequate formal support.

• Clinical Guideline Quality and Equity: Only 26.1% of dementia care guidelines incorporated people with lived experience, and just 43.5% addressed health equity considerations. Variability in recommendation statements and insufficient attention to guideline applicability continue to impede consistent implementation across clinical settings.

• End-of-Life Care Quality: The protracted and unpredictable disease trajectory of advanced dementia poses multifaceted challenges for end-of-life care. Future palliative interventions must be grounded in evidence-based content development and prioritize improved engagement between patients, caregivers, and healthcare professionals to support dignified death.